Intra-Cellular’s CAPLYTA (lumateperone) Receives the US FDA’s Approval for the Treatment of Schizophrenia in Adults

 Intra-Cellular’s CAPLYTA (lumateperone) Receives the US FDA’s Approval for the Treatment of Schizophrenia in Adults

Shots:

  • The approval is based on the study assessing CAPLYTA (42 mg) vs PBO while keeping Positive and Negative Syndrome Scale (PANSS) as 1EP
  • The study resulted in somnolence/sedation (24% vs.10%) and dry mouth (6% vs. 2%)
  •  CAPLYTA is a once-daily, oral therapy mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors

Click here to read full press release/ article | Ref: Intra-Cellular | Image: Behance

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post